Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Diseases
29%
Ibrutinib
26%
Venetoclax
22%
Lymphocytic Lymphoma
22%
Duvelisib
14%
Progression Free Survival
12%
Bruton Tyrosine Kinase Inhibitor
10%
Minimal Residual Disease
10%
Chronic Lymphocytic Leukemia
9%
Cancer
8%
Adverse Event
8%
B Cell
8%
Leukemia
7%
Mantle Cell Lymphoma
7%
Chemoimmunotherapy
6%
Minimal Change Disease
5%
Stem Cell
5%
Fludarabine
5%
Mogamulizumab
5%
Arm
5%
Neutropenia
5%
Disease Exacerbation
5%
Overall Survival
5%
Rituximab
5%
Clinical Trial
5%
Cyclophosphamide
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
62%
Duvelisib
29%
Lymphocytic Lymphoma
25%
Diseases
22%
Ofatumumab
17%
Ibrutinib
17%
Fludarabine
17%
Venetoclax
14%
Cyclophosphamide
13%
Progression Free Survival
12%
Rituximab
11%
Minimal Residual Disease
10%
Porous Silicon
8%
Nanoparticle
8%
Small Interfering RNA
8%
Overall Survival
7%
Disease Exacerbation
6%
Obinutuzumab
5%
Chlorambucil
5%
Polyethyleneimine
5%
Bruton Tyrosine Kinase Inhibitor
5%
Neutropenia
5%
Biochemistry, Genetics and Molecular Biology
Trisomy
13%
Fluorescence in Situ Hybridization
10%
B Cell
7%
Lipid
5%
Cytometry
5%
Chromosome 16
5%
Flow Cytometry
5%
Proteomics
5%